Drug Profile
Research programme: therapeutic HBV vaccines - Profectus Biosciences
Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Profectus Biosciences
- Class Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Hepatitis B (Adjunctive treatment) in USA (Parenteral)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Hepatitis-B(Adjunctive treatment) in USA (Parenteral)
- 27 Jul 2016 Preclinical trials in Hepatitis B in USA (Parenteral)